Show simple item record

dc.contributor.authorHultcrantz, M
dc.contributor.authorPfeiffer, R M
dc.contributor.authorBjörkholm, M
dc.contributor.authorGoldin, L R
dc.contributor.authorTuresson, I
dc.contributor.authorSchulman, S
dc.contributor.authorLandgren, O
dc.contributor.authorKristinsson, S Y
dc.date.accessioned2015-05-04T11:24:58Zen
dc.date.available2015-05-04T11:24:58Zen
dc.date.issued2014-11en
dc.date.submitted2015en
dc.identifier.citationJ. Thromb. Haemost. 2014, 12 (11):1816-21en
dc.identifier.issn1538-7836en
dc.identifier.pmid25196979en
dc.identifier.doi10.1111/jth.12724en
dc.identifier.urihttp://hdl.handle.net/2336/552114en
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractMany malignancies, including multiple myeloma and its precursor, monoclonal gammopathy of unknown significant, are associated with an elevated risk of thromboembolism. There is limited information on the risk of thrombosis in patients with Waldenström macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL).
dc.description.abstractTo assess the risk of venous and arterial thrombosis in WM/LPL patients in a large population-based cohort study in Sweden.
dc.description.abstractA total of 2190 patients with WM/LPL and 8086 matched controls were identified through Swedish registers between 1987 and 2005. Information on occurrence of venous and arterial thrombosis after the diagnosis of WM/LPL was obtained through the centralized Swedish Patient Register, with follow-up to 2006. Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).
dc.description.abstractPatients with WM/LPL had a significantly increased risk of venous thrombosis and the highest risk was observed during the first year following diagnosis (HR = 4.0, 95% CI 2.5-6.4). The risk was significantly elevated 5 (HR = 2.3, 95% CI 1.7-3.0) and 10 years after diagnosis (HR = 2.0, 95% CI 1.6-2.5). There was no increased risk of arterial thrombosis during any period of follow-up time (10-year HR = 1.0, 95% CI 0.9-1.1).
dc.description.abstractVenous thrombosis is a significant cause of morbidity in patients with WM/LPL. The potential role of thromboprophylaxis in WM/LPL, especially during the first year after diagnosis and in patients treated with thrombogenic agents, needs to be assessed to further improve outcome in WM/LPL patients.
dc.language.isoenen
dc.publisherBlackwell Puben
dc.relation.urlhttp://dx.doi.org/ 10.1111/jth.12724en
dc.rightsArchived with thanks to Journal of thrombosis and haemostasis : JTHen
dc.subjectKrabbameinen
dc.subjectEitlaren
dc.subject.meshWaldenstrom Macroglobulinemiaen
dc.subject.meshEmbolism and Thrombosisen
dc.subject.meshLymphoma, B-Cellen
dc.subject.meshThrombosisen
dc.subject.meshVenous Thrombosisen
dc.titleElevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Swedenen
dc.identifier.journalJournal of thrombosis and haemostasis : JTHen
dc.rights.accessOpen Access - Opinn aðganguren
html.description.abstractMany malignancies, including multiple myeloma and its precursor, monoclonal gammopathy of unknown significant, are associated with an elevated risk of thromboembolism. There is limited information on the risk of thrombosis in patients with Waldenström macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL).
html.description.abstractTo assess the risk of venous and arterial thrombosis in WM/LPL patients in a large population-based cohort study in Sweden.
html.description.abstractA total of 2190 patients with WM/LPL and 8086 matched controls were identified through Swedish registers between 1987 and 2005. Information on occurrence of venous and arterial thrombosis after the diagnosis of WM/LPL was obtained through the centralized Swedish Patient Register, with follow-up to 2006. Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).
html.description.abstractPatients with WM/LPL had a significantly increased risk of venous thrombosis and the highest risk was observed during the first year following diagnosis (HR = 4.0, 95% CI 2.5-6.4). The risk was significantly elevated 5 (HR = 2.3, 95% CI 1.7-3.0) and 10 years after diagnosis (HR = 2.0, 95% CI 1.6-2.5). There was no increased risk of arterial thrombosis during any period of follow-up time (10-year HR = 1.0, 95% CI 0.9-1.1).
html.description.abstractVenous thrombosis is a significant cause of morbidity in patients with WM/LPL. The potential role of thromboprophylaxis in WM/LPL, especially during the first year after diagnosis and in patients treated with thrombogenic agents, needs to be assessed to further improve outcome in WM/LPL patients.


This item appears in the following Collection(s)

Show simple item record